Archive for the ‘Health Care Stocks’ Category

TSON in orbit, CSCO buzzes, EBIX swoons

Thursday, March 24th, 2011

TranS1 Inc. (Nasdaq: TSON) shares gained 25.8% to $4.10. Volume was 8.2 million shares, up against a daily average of only 172,000, after the medical-device manufacturer said U.S. regulators had cleared its spinal implant system.

Cisco Systems Inc. (Nasdaq: CSCO) was a volume champion Thursday, with 51.3 million shares changing hands, still below its average of 71.5 million. Share prices for CSCO were down, however, by 1.3% to $17.36.

Ebix Inc. (Nasdaq: EBIX) suffered a price nosedive of 24.2% Thursday to $22.53, on volume of 14.1 million shares, towering over its average of 575,442. Monitoring system BUYINS.NET announced it was updating its coverage of EBIX.

WOLF howls, DSCM being bought, MNOV slumps

Thursday, March 24th, 2011

Great Wolf Resorts, Inc.(NASDAQ: WOLF) shares jumped 7.2% to $2.23, after it announced that it has completed the sale of its Blue Harbor Resort in Sheboygan, Wisconsin, to Claremont New Frontier Resort LLC for $4.2 million.

drugstore.com, inc. (Nasdaq: DSCM) did incredible business Thursday, trading in 53.7 million shares, dwarfing its daily average of 849,685. Share prices for DSCM skyrocketed 111.2% to $3.78, on news Walgreen (NYSE: WAG) was buying the chain for $429 million in cash.

MediciNova Inc. (Nasdaq: MNOV) plummeted in price by 23.3% to $2.73 Thursday. Volume for the stock 850,000 shares, leaving its average of 13,364 in the dust, a day after MNOV priced a firm-commitment underwritten public offering of 2,750,000 units at a price to the public of $3.00 per unit for gross proceeds of $8.25 million.

PFSW soars, MU far from mute, MSHL moody

Wednesday, March 23rd, 2011

PFSWEb Inc. (Nasdaq: PFSW) stepped on the accelerator Wednesday, gaining 25.4% in price to $4.15. Volume for the stock was nearly 630,000 shares, trouncing its daily average of 86,789, on better-than-expected Q4 earnings.

Micron Technology Inc. (Nasdaq: MU) proved among the busiest stocks on Wall St. Wednesday, trading in 39.5 million shares, just shy of its daily average around 41 million. Share prices budged 2.7% higher to $10.62, as investors awaited the release of MU’s Q2 financials results.

Marshall Edwards Inc. (Nasdaq: MSHL) slumped 15.7% Wednesday to register at $1.56 near the close. Volume for the stock was 143,091, or nearly double its usual volume.

OMER gets traction, SIRI gets sued, CREE gets dumped

Wednesday, March 23rd, 2011

Omeros Corp. (Nasdaq: OMER) shares gained 10.6% to $6.69. Volume was 154,491 shares, or 2 and a half times the norm, after the biotechnology company said its potential eye-surgery treatment met key goals in a mid-stage study.

Sirius XM Radio Inc. (Nasdaq: SIRI) traded in 44.7 million shares by noon ET Wednesday, in contrast to a daily average of 55.9 million. Share prices dipped a bit, though, by 2.4% to $1.67, after Howard Stern sued the satellite radio provider and at least one analyst cut his rating on the stock.

Cree Inc. (Nasdaq: CREE) shares fell 11.7% to $43.29, on volume of 14.2 million, towering over its average of 3.3 million, after the LED manufacturer trimmed its third-quarter revenue forecast.

DYSL barrels out of blocks, C hires, XOMA trails off

Wednesday, March 23rd, 2011

Dynasil Corporation (Nasdaq: DYSL) shares skyrocketed 70.2% to $6.62, on volume of 156,500 shares, towering over its average of 9,172 a day, after it announced that its research division was granted additional U.S. patent claims for advances in a detector material capable of responding independently to both neutron and gamma radiation.

Citigroup Inc. (NYSE: C) was a volume leader in early trading on Wednesday, dealing in 114.7 million shares, against a full-day average of 487.6 million. Share prices eased 1.6% to $4.35, after C announced the hiring of former StanChart banker Martin Lovegrove to head its energy services division.

Xoma Ltd. (Nasdaq: XOMA) shares were off 28.5% to $3.59, on volume of 2.6 million, catching up on a daily average of 4.2 million, a day after the company said a diabetes-treatment candidate did not yield better results than a placebo in a study.